Hansa Partner Sarepta Therapeutics Plans to Initiate a Clinical Study of Imlifidase for Duchenne Muscular Dystrophy
Shots:
- The company will initiate a clinical study of imlifidase in patients with DMD with pre-existing IgG Abs to Sarepta's SRP-9001. The study is expected to be commenced in 2023
- In the preclinical studies, the results showed the ability of imlifidase to reduce pre-existing IgG Abs to rAAVrh74 for safe & successful administer SRP-9001. Imlifidase is marketed under the trade name Idefirix & has conditional marketing approval in the EU for highly sensitized adult kidney transplant patients who have a positive crossmatch against an available deceased donor
- In 2020, Sarepta got exclusive rights globally for imlifidase as a pre-treatment for DMD & LGMD where Hansa received ~$397.5M in development, regulatory & sales milestones along with royalties
Ref: PRNewswire | Image: Hansa
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
